Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 502,741
  • Shares Outstanding, K 137,361
  • Annual Sales, $ 36,780 K
  • Annual Income, $ -159,690 K
  • 60-Month Beta 2.29
  • Price/Sales 3.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.44
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.43 +6.55%
on 02/06/20
4.07 -10.07%
on 01/17/20
+0.16 (+4.57%)
since 01/14/20
3-Month
3.31 +10.57%
on 01/13/20
4.57 -19.91%
on 11/19/19
-0.08 (-2.14%)
since 11/14/19
52-Week
2.13 +71.43%
on 08/05/19
4.57 -19.91%
on 11/19/19
+0.12 (+3.39%)
since 02/14/19

Most Recent Stories

More News
Agenus Announces Investor Day on February 20, 2020

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February...

AGEN : 3.66 (unch)
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President...

AGEN : 3.66 (unch)
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

EBS : 63.17 (+0.27%)
AGEN : 3.66 (unch)
GILD : 67.56 (+1.14%)
BOLD : 59.97 (-0.02%)
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products. While agriculture, material science and environmental science are...

TOMDF : 0.0400 (+33.78%)
AGEN : 3.66 (unch)
LPTX : 2.15 (+6.97%)
TRIL : 3.44 (-4.97%)
VSTM : 2.00 (-0.50%)
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

AMRN : 17.62 (-0.40%)
FOLD : 10.98 (+0.09%)
AGEN : 3.66 (unch)
AQB : 1.65 (-6.25%)
Agenus Commences Phase 1 trial with AGEN1223

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is...

AGEN : 3.66 (unch)
Innate Pharma's Filing for Leukemia Drug Accepted in Europe

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

AZN : 47.85 (-3.00%)
AGEN : 3.66 (unch)
NCNA : 5.47 (+4.79%)
IPHA : 7.40 (-4.27%)
Pulmatrix Surges on License Agreement With Johnson & Johnson

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

JNJ : 150.13 (+0.03%)
CHRS : 21.74 (-1.05%)
PULM : 1.49 (+3.47%)
AGEN : 3.66 (unch)
Amicus Progresses on Pipeline Development Amid Competition

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

SNY : 49.93 (-0.14%)
FOLD : 10.98 (+0.09%)
ALXN : 102.56 (-0.83%)
AGEN : 3.66 (unch)
Arena (ARNA) Expands Strategic Deal With Beacon Discovery

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

CHRS : 21.74 (-1.05%)
AGEN : 3.66 (unch)
ARNA : 54.00 (+0.33%)
UTHR : 104.19 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AGEN with:

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

2nd Resistance Point 3.81
1st Resistance Point 3.74
Last Price 3.66
1st Support Level 3.57
2nd Support Level 3.47

See More

52-Week High 4.57
Last Price 3.66
Fibonacci 61.8% 3.64
Fibonacci 50% 3.35
Fibonacci 38.2% 3.07
52-Week Low 2.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar